Articles tagged with Colorectal Cancer
Research from Radboud University Medical Center and colleagues demonstrates the value of targeted tumor analysis of DNA in colorectal polyps. This study provides valuable insights into genetic predispositions, including APC mutational mosaicism and BRAF gene mutations.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
Researchers identified specific microbial patterns associated with tumor location, genetic features, and patient outcomes. A new Microbial Risk Score (MRS) offers a practical way to translate complex microbiome data into prognostic insight.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
A community awareness campaign in Nigeria increased awareness of colorectal cancer symptoms and risk factors, leading to earlier detection of the disease. The program also identified precancerous polyps and detected colorectal cancer at curable stages.
Researchers at Kyoto University identified five molecular subtypes of colorectal cancer stem cells and developed a practical prognostic indicator, the general colorectal cancer signature (GCS), to predict patient outcomes. The GCS was validated with a novel orthotopic xenograft mouse model and showed promising clinical significance.
Researchers used machine learning to combine clinical data with biological markers, achieving 89.58% accuracy in predicting patient survival. The study identified key markers such as E2F8, WDR77, and hsa-miR-495-3p, which were associated with tumor growth and cancer development.
BGI Genomics convened its 2025 European Partnership & Networking Summit in Budapest, fostering innovation, collaboration, and growth. The event introduced its comprehensive NGS solution, Gensiro, integrating AI and automation to streamline laboratory workflows.
Researchers from MSK discovered that two distinct subtypes of regulatory T cells play opposing roles in colorectal cancer, with one restraining tumor growth and the other fueling it. The study suggests that selective approaches to targeting these cells could improve immunotherapy treatment for most patients with colorectal cancer.
The grant aims to increase individual screenings and change how health systems embed evidence-based screening practices into everyday operations. PA-CARES will work with trusted organizations in 28 counties with the lowest screening rates to implement effective screening options and facilitate timely linkage to care.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
Researchers found that sudden cardiac death (SCD) among colorectal cancer patients decreased overall, but disparities remained based on age, sex, and geographic location. The study highlights the need for tailored heart monitoring and care strategies for cancer patients, particularly in underserved groups.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
This study reveals significant viral-host interactions in colorectal polyps, identifying specific viruses associated with oncogenic and tumor-suppressive transcriptomic profiles. The findings suggest that viral activity contributes to early neoplastic transformation, challenging the traditional view of viruses as mere bystanders.
A new review connects gut microbiome imbalances to obesity, metabolic syndrome, and colorectal cancer, highlighting the potential for diet and microbiome-based treatments. The study also explores racial and socioeconomic disparities in microbiome-related diseases, emphasizing the need for inclusive prevention strategies.
A new study reveals that social determinants of health have a significant impact on rural–urban differences in colorectal cancer mortality rates. The research found that low socioeconomic status, household characteristics, and racial/ethnic minority status were key drivers of these disparities.
Researchers at MD Anderson have discovered bacterial genetic and cellular elements within brain tumor cells, potentially influencing tumor behavior. Inflammation may also drive the earliest stages of lung cancer, with targeting proinflammatory pathways emerging as a potential early intervention approach
Researchers found that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the USPSTF lowered the recommended screening age to 45. Despite investigating unmet social needs, no significant differences were found in testing uptake for this early midlife cohort.
A new bio-heterojunction platform integrates electrogenic bacteria with piezoelectric nanoparticles to eradicate colorectal tumors and restore the gut microbiome. The platform induces two distinct forms of tumor cell death, apoptosis and pyroptosis, and effectively remolds the tumor microenvironment.
A study of nearly 30,000 female nurses found that consuming more ultra-processed foods was associated with a 45% higher risk of developing adenomas, precursors to early-onset colorectal cancer. The study's findings support the importance of reducing ultra-processed food intake as a strategy to mitigate the rising burden of early-onset ...
Researchers developed a new DNA analysis technique to study old genetic samples, shedding light on disease evolution and changes in biology over time. The approach has potential for unlocking the root causes underlying shifting landscapes of modern diseases.
A study found that higher consumption of ultraprocessed foods is associated with an increased risk of developing early-onset colorectal cancer precursors. The research highlights the importance of improving dietary quality to mitigate the rising burden of early-onset colorectal cancer.
A new study from Mass General Brigham researchers identified distinct T-cell infiltration patterns in colorectal cancer precursor lesions and cancer tissues. The findings suggest that understanding these patterns could help detect CRC earlier by predicting risk and develop therapeutic approaches.
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
Research highlights the importance of mitochondria-endoplasmic reticulum cross-talk in colorectal cancer, regulating Ca2+ homeostasis and lipid metabolism. Novel therapeutic strategies targeting this crosstalk may suppress CRC progression and improve patient outcomes.
A study reveals how colorectal tumors use TGF-β to prevent immune cells from reaching and attacking the tumor. The researchers suggest strategies to improve immunotherapy efficacy by blocking this dual barrier and identifying new therapeutic targets.
A cohort study finds nearly 10-fold increase in facility-based screening among 45-49 year olds after USPSTF guideline changes. This rapid growth highlights early implementation by practitioners and patients, far exceeding growth among those ages 50 to 75.
Colorectal cancer screening modities shifted among privately insured individuals after COVID-19, with decreased colonoscopy and fecal tests, increased stool DNA tests. Differences found by sex, socioeconomic status, and metropolitan area residence.
Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.
The study reveals geographic clusters of high and low screening for breast, cervical, and colorectal cancers in the US Northeast and Southwest. Future studies could examine county-level healthcare access to optimize cancer screening practices.
Researchers at UC Irvine have developed a 3D human colon model integrated with bioelectronics to aid in colorectal cancer research and drug discovery. The model shows promising results in detecting resistance to chemotherapy drugs, making it a potential alternative to traditional animal testing.
Researchers at UT Austin have developed a new cancer treatment that uses LED light and SnOx nanoflakes to precisely target cancer cells without harming healthy ones. The treatment achieved remarkable effectiveness in neutralizing colorectal and skin cancer cells, with up to 92% kill rate in just 30 minutes of exposure.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
Researchers found microplastic exposure changes the human gut microbiome, with some shifts resembling patterns linked to diseases. Microplastic-induced changes in microbial composition may serve as a bacterial stress response, potentially affecting overall well-being.
Researchers found that rectal bleeding increases the odds of a colorectal cancer diagnosis by 8.5 times in patients under 50, highlighting the need for symptom-driven care and lifestyle modifications to reduce the risk. The study analyzed 443 patients and identified no family history as a factor in early-onset colorectal cancers.
A California court has ruled that processed meat, classified as a carcinogen by the World Health Organization, should not be included on the state's Proposition 65 list. This decision endangers public health and increases colorectal cancer risk, particularly among younger people.
The University of Cincinnati Cancer Center is conducting a study on combining KRAS inhibitors with HER3 targeted agents to treat colorectal cancers. The goal is to extend patient lives and reduce toxic treatments. Researchers hope to develop new, less-toxic options for patients whose cancer has spread.
Researchers at Mayo Clinic identified a genetic factor contributing to severe liver damage after chemotherapy for colorectal cancer patients. A specific gene variant, PNPLA3, was linked to increased risk of liver injury.
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
A 71-year-old man was diagnosed with advanced colorectal cancer after suffering from multiple unexplained strokes and blood clots. The cancer remained undetected until widespread clot complications appeared, highlighting the need for comprehensive oncologic evaluation in patients with unexplained hypercoagulable states.
Researchers developed an engineered strain of gut-homing bacteria that induces mature tertiary lymphoid structures, associated with improved survival and stronger treatment responses. The therapy also restored healthy gut microbiota and showed excellent biocompatibility.
A new study found that sugary drinks can fuel metastasis in preclinical models of advanced colorectal cancer by activating an enzyme called sorbitol dehydrogenase. This pathway is also targeted by statins, common heart drugs. Reducing sugary drink consumption and targeting this enzyme may offer opportunities to reduce metastasis.
A randomized clinical trial shows that low-dose aspirin reduces the risk of recurrence by 55% in patients with colon and rectal cancer harboring a specific genetic mutation. Aspirin's anti-inflammatory and anti-tumor effects may be responsible for its therapeutic benefits.
A blood test using microbial DNA analysis can distinguish primary liver cancer from colorectal cancer that has spread to the liver, according to a new study. The test reveals distinct bacterial 'fingerprints' for each cancer type, making it a powerful tool for non-invasive diagnosis and potential future therapy guidance.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
A new study found that providing personalized colorectal cancer risk information to patients and their health care providers did not improve screening rates for the deadly ailment. Colorectal cancer is the second-most common cause of death from cancer in the United States, claiming nearly 55,000 lives annually.
Researchers found that colorectal cancer cells stimulate cancer-associated fibroblasts to produce collagen through TGF-β1-induced de novo glycine synthesis. PHGDH is identified as a potential therapeutic target for treating colorectal cancer.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
A large-scale study found that genetic variants and ancestry play a significant role in colorectal cancer risk in Brazil. The study identified nine genetic variants associated with disease risk, including four that contributed to the risk independently of other factors.
A randomized controlled trial found that personalized risk messages failed to increase colorectal cancer screening participation. Despite the lack of improvement, researchers emphasize the importance of continued research and potential improvements for uptake, effectiveness, and efficiency of CRC screening.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Recent advancements in screening methods and point-of-care diagnostics offer hope for early detection and improved outcomes in colorectal cancer. Emerging technologies such as single-cell sequencing, spatial transcriptomics, and artificial intelligence are being leveraged to enhance diagnostic accuracy and personalized risk prediction.
Researchers found that patients carrying colibactin-producing Escherichia coli in their colon polyps were more than three times as likely to have a history of colorectal cancer compared to those without the bacterium. The study suggests that targeting specific microbes could help prevent cancer in high-risk groups.
A novel AI model developed by the Dresden research team simultaneously detects multiple genetic alterations directly from routinely stained histological colon cancer tissue sections. The model recognized shared visual patterns rather than independently identifying individual genetic alterations.
A new study found a strong association between accelerated epigenetic aging and increased risk of colorectal cancer in postmenopausal women. Lifestyle factors like diet significantly influenced this risk, with healthy diets potentially reducing cancer risk associated with biological aging.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A nationwide Swedish study found nearly three times as many young adults under 50 diagnosed with colorectal cancer today compared to the early 1990s. The disease has become two to three times more common in this age group, with underlying causes not fully understood.
A study published in The Lancet Gastroenterology & Hepatology found that routine AI assistance during colonoscopies can lead to a decrease in the ability of endoscopists to detect precancerous growths without AI aid. This reduction in skills may impact patient-related outcomes and highlight the need for further research on the long-ter...